"BIT225, Biotron’s lead antiviral clinical-stage,...

"BIT225, Biotron’s lead antiviral clinical-stage, investigational, small molecule antiviral drug, has, in addition to its unique clinical activity against HIV-1, shown very good activity against SARS-CoV-2 and prevented development of disease in a COVID-19 mouse model (ASX announcements 25 November 2021, 17 March 2022 and 2 May 2022).

The SARS-CoV-2-infected mice quickly died from respiratory disease very similar to human COVID-19. However, BIT225 very efficiently reduced levels of SARS-CoV-2 virus and stopped the life-threatening cytokine storm. The mice treated with BIT225 did not develop any signs of disease and remained healthy throughout the several studies that were conducted."

"Following the success of the COVID-19 mouse model study, in May 2023 the Company commenced a Phase 2 clinical trial (BIT225-012) at sites in Thailand for the treatment of COVID-19 in humans."

"In August 2023, all participants in the BIT225-12 COVID-19 Phase 2 clinical trial completed dosing, marking the end of the clinical phase of the trial. Work is now focused on completing the laboratory analyses of samples collected during the trial."

"Preliminary results from the BIT225-012 COVID19 trial are expected to be available in September 2023, subject to finalisation of detailed laboratory and other data analyses."

Some extracts from the August preliminary report, on a post light day, just a reminder why some of us are excited about the prospects for this company and more importantly the health of the human population on the planet.